PR Newswire
NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies –
– Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy –
– Advanced the Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) –
BOULDER, Colo., Aug. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2025 and recent business highlights.
NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Edgewise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings –
– Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker –
– Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 –
– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event –
BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results in its sevasemten program for Becker and Duchenne muscular dystrophies.
BOULDER, Colo., June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) –
– Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million –
– On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 –
– Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 –
BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025, subject to the satisfaction of customary closing conditions.
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM –
– Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function –
– EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% –
BOULDER, Colo., March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET. The team is excited to be joined by two of the Company's CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page.
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.